JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266268

Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PRCC KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 13 bp deletion in exon 1 and 186 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

PRCC_HUMAN, Papillary renal cell carcinoma (Translocation associated), isoform CRA_b, Papillary renal cell carcinoma translocation-associated gene protein, Proline-rich protein PRCC, RCCP1, TPRC

2 Images
Sanger Sequencing - Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line (AB266268)
  • Sanger seq

Unknown

Sanger Sequencing - Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line (AB266268)

Allele-1 : 13 bp deletion in exon1

Sanger Sequencing - Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line (AB266268)
  • Sanger seq

Unknown

Sanger Sequencing - Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line (AB266268)

Allele-2 : 186 bp deletion in exon 1.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 13 bp deletion in exon 1 and 186 bp deletion in exon 1

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266268-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266268-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266268 Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line", "number":"AB266268-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266268-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266268-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266268 Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line", "number":"AB266268-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266268-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266268 Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line", "number":"AB266268-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266268-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266268 Human PRCC (Papillary renal cell carcinoma) knockout HEK-293T cell line", "number":"AB266268-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PRCC
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Papillary renal cell carcinoma (PRCC) also known as papillary renal is a significant variant of kidney cancer. It arises mechanically from the epithelial cells of the kidney tubules that exhibit papillary growth patterns. PRCC lacks a single protein target but involves various changes on the molecular level often linked to genetic alterations such as mutations in the MET oncogene. These changes can affect cell surface expression and signal pathways. The mass or size data about individual protein targets in this context is not typically described due to the complex and multi-genetic nature of PRCC.
Biological function summary

PRCC forms as a type of cancer characterized by the formation of finger-like projections in the kidney. It does not align to a single protein or simple biological function but involves components like alterations in the MET pathway an independent complex soliciting increased proliferative and migratory signals within renal tissues. This process can lead to the unusual cell growth that distinguishes PRCC in affected kidneys.

Pathways

MET signaling pathway and the associated HGF (hepatocyte growth factor) signaling cascade are closely involved in papillary renal phenotypes. These pathways contribute significantly to cell growth migration and differentiation regulation within the renal system. It's related to proteins such as RAS and PI3K which play essential roles in further amplifying cellular signals that contribute to oncogenesis.

PRCC is closely linked to kidney cancer specifically identified in renal cell carcinoma spectrum. Genetic evidence connects PRCC to von Hippel-Lindau (VHL) disease a disorder known to predispose individuals to various tumors. The VHL protein exhibits abnormal function in both VHL disease and PRCC highlighting its role in disease progression and potential as a therapeutic target. Additionally the involvement of the MET protein stands out as a specific player in familial cases of PRCC contributing to an inherited predisposition to this type of cancer.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com